Introduction {#sec1}
============

Oral lesions form significant early clinical features of HIV infection \[[@cit0001]\]. These lesions are often indicators of immune suppression and can be used for early testing, diagnosis and management of patients with HIV/ AIDS. Oral lesions therefore contribute largely to patients\' morbidity, affecting the psychological and economic functioning of the individual and community \[[@cit0002]\]. They may be classified into infections such as fungal, viral and bacterial infections, neoplasms such as Kaposi\'s sarcoma and non-specific presentations such as aphthous ulcerations and salivary gland diseases \[[@cit0003], [@cit0004]\]. The overall prevalence of oral lesions in HIV infected patients has changed since the advent of combination Anti-Retroviral Therapy (cART). For instance, several studies have shown considerable reduction in prevalence of herpes labialis and periodontal diseases along with other oral lesions from 80% to about 30% after the institution of cART \[[@cit0005]\] and in HIV-associated opportunistic infections \[[@cit0006], [@cit0007]\]. Oral candidiasis (OC) has been shown to be the most common oral lesion seen in HIV infected patients, however with the advent of cART, most studies reported a decline in its occurrence. In a study of 93 patients, 7% of patients on protease inhibitors (PI) had oral candidiasis, compared with 36% in non-PI treated patients \[[@cit0008]\]. Schmidt-Westhausen *et al.* (2000) detected OC in 10 out of 103 (9.7%) of their study subjects who had been on cART for 4 weeks and in none after 6 months of therapy (N=61) \[[@cit0009]\]. Unlike most other oral manifestations of HIV, which decrease with use of cART, studies from the USA and the United Kingdom (UK) have described an increase in the prevalence of oral warts with cART \[[@cit0010]-[@cit0012]\], which may reach statistical significance.

Other lesions that are showing a trend of rising prevalence include HIV- related salivary gland disease \[[@cit0010]\]. The goal of cART should be maximal and durable viral suppression, restoration and preservation of the immune system with resultant resolution of opportunistic illnesses and improvement in the quality of life through ease of use of the regimen with minimal side-effects to enhance adherence. This should translate to a reduction of HIV-related morbidity including oral manifestations. Reduction of viral load will prevent progressive immunodeficiency, decrease the risk of the emergence of resistant viruses and decrease the risk of viral transmission \[[@cit0013]\]. The potent combination therapies have proven effective in suppressing plasma-HIV viral load below detectable limits and elevating CD4+ lymphocyte cell counts. Consequently, the immune status for the therapy adherent patients improves significantly. However, some patients fail to achieve complete viral suppression \[[@cit0014], [@cit0015]\]. It has been shown in various studies that the prevalence of HIV-related oral lesions reduces significantly with cART. The reported percentage decrease varied from 10% in a USA study on 570 patients \[[@cit0010]\] to 50% in a Mexican study on selected 1000 HIV patients over a period of 12 years \[[@cit0016]\]. In a Nigerian study about 80% of the lesions cleared with use of cART \[[@cit0007]\]. However, cART sometimes achieves suboptimal results with less than fifty percent of patients achieving therapeutic goal. This is due to a variety of reasons such as medication intolerance/ side effects, prior ineffective antiretroviral therapy and infection with a drug-resistant strain of HIV. However, non-adherence with antiretroviral therapy is the major reason most individuals fail to benefit from cART \[[@cit0017]\]. Nearly all the reported studies had been conducted in industrialised countries and literatures concerning the behaviour of HIV related oral lesions in patients undergoing cART is scarce. This study therefore seeks to determine the prevalence of HIV related oral lesion on patients undergoing cART therapy and to assess the therapeutic effects of cART on the clinical presentations of these lesions and its relation to CD4+ cell count in a Nigerian adult population.

Methods {#sec2}
=======

A cross-sectional study was conducted in 491 HIV infected patients on cART therapy, who attended the HIV Clinics of the Lagos University Teaching Hospital (LUTH) and the Nigerian Institute of Medical Research (NIMR). The study was conducted over a period of 5 months and the patients were assessed for presence or absence of HIV-related oral lesions conforming to EC-Clearinghouse, 1993 guidelines on the diagnostic criteria for classifying oral lesions in HIV \[[@cit0018]\]. Data were collected using a structured interviewer administered questionnaire which included their demographic data, information regarding the time of testing for HIV, source of the disease, if they noticed any previous oral or facial lesions or conditions prior to presentation, how they treated these conditions, if there were improvement with local treatment. History of use of cART were also obtained from the patients, for example- duration of use, names of the specific drugs, reasons for change if any, use if consistent or haphazard, and improvement after therapy. Clinical examination was done with the aid of sterile dental instruments under bright light source. Information obtained included; oral hygiene status, presence of HIV related oral lesions and other lesions like dental caries, tooth discoloration and so on. Laboratory investigations included; HIV screening and CD4+ cell count which were obtained at start of cART and latest test result at the time of examination for the study documented.

Participants were grouped into 3 based on the CDC immunologic classification (category) for HIV infection; those with CD4+ cell count ≥ 500/mm^3^ were classified as group I, those with CD4+ cell count between 200/mm^3^ and 500/mm^3^ were classified as group II and those with CD4 + cell count \< 200/mm^3^ were classified as group III. Viral load results were not obtained for majority of the patients due to challenges related to provision of the test. Information regarding treatment of patients with cART was also obtained - name of medications, duration of use and previous medications used were all documented. Ethical approval was given by the Ethics and Research Committee of the Lagos University Teaching Hospital, along with permission from the Deputy Director of Research NIMR. After full explanation of the study to patients; those who declined were excluded while those who gave consent were recruited into the study. Both verbal and written consent were obtained from all the respondents. Privacy and confidentiality were managed by examining the recruited patients in private as well as prior coding of administered questionnaires. Data were analysed using the software SPSS for windows (version 21: SPSS Chicago, IL). Categorical data were presented as numbers and percentages and continuous data as mean ± standard deviation; where data was parametric and median values (interquartile range) utilized for non-parametric data. Chi square test was used to assess the relationship between categorical variables. Fisher\'s exact test was used for 2 × 2 tables or where the requirements for test could not be met. Paired T test applied to compare mean CD4 cell count at initiation of cART and on examination at recruitment. The 5% significance level was used.

Results {#sec3}
=======

A total of 491 people living with HIV on cART were enrolled into the study. Participants age range between 18-80 years, with a mean of 41.2 ± 9.1 years. There were 367(74.7%) females and 124(25.3%) males with a female to male ratio of 3:1. Most of the participants were married (66.9%), and up to 44.0% of them had at least secondary school education. Igbo ethnic group represented the most prevalent group (191, 38.9%) followed closely by Yoruba ethnic group (168, 34.2%). Majority 439(89.4%) of the PLWHIV in this study claim to be Christians, while very few of them (11.2%) consume alcohol and cigarette smoking habit was very rare (2.9%) [Table 1](#t0001){ref-type="table"}. Seventy-two (14.7%) of the respondents gave a history of presence of oral lesions suggestive of HIV infection prior to commencement of cART, while 85.3% had never experienced oral lesions suggestive of HIV. Of those who gave a history of oral lesions, 28(38.9%) claimed these lesions cleared after the administration of cART alone, while 21(29.2%) acknowledged the use of other medications along with cART to treat the lesions. The median duration of oral lesions was 9 ±(1-36) months and recurrence was reported in 18(26%) of the respondents ([Table 2](#t0002){ref-type="table"}). Distributions of oral lesions are shown in [Table 2](#t0002){ref-type="table"}. Majority 426 of the total number of patients in this study had been diagnosed of HIV for over a year while the remainder 65 were diagnosed within one year. Only 12(2.4%) of the participants had observable oral lesions suggestive of HIV, and 10 of these lesions were hyperpigmentation of the oral mucosa primarily affecting the tongue and the buccal mucosa. The other patients had oral ulcers suggestive of aphthous ulcerations ([Table 3](#t0003){ref-type="table"}). A total of six out of the 10 patients with oral hyperpigmentation were on regimen containing Lamivudine (75%), this was followed by regimen containing Tenofovir 5(62.5%).

###### 

demographic data of HIV patients on HAART

                                    Frequency      Percentage (%)
  --------------------------------- -------------- ----------------
  **Demographic data**                             
  Age (mean in years)               41.22 ± 9.06   
                                    Range: 18-80   
  **Sex**                                          
  Male                              125            25.4
  Female                            366            74.4
  **Marital status**                               
  Single                            96             19.6
  Married                           328            66.8
  Divorced                          25             5.1
  Widowed                           41             8.4
  **Level of education**                           
  None                              6              1.2
  Primary                           102            20.8
  Secondary                         215            43.8
  Tertiary                          168            34.2
  **Religion**                                     
  Christianity                      459            89.4
  Islam                             51             10.4
  Others                            1              0.2
  **Ethnic group**                                 
  Yoruba                            167            34.0
  Igbo                              191            38.9
  Hausa                             10             2.0
  Ijaw/Edo                          34             6.9
  Efik                              28             5.7
  Others                            61             12.4
  **Bio demographic data**                         
  Cigarette smoking                                
  Yes \*                            14             2.9
  No                                477            97.1
  **Alcohol consumption**                          
  Yes\*                             57             11.2
  No                                451            88.8
  **Route of infection \*\***                      
  Sexual route                      44             9.0
  Single partner                    62             12.6
  Multiple partner                  15             3.1
  Same sex partner                  7              1.4
  Sharing sterile instruments       28             6.1
  Blood transfusion                 21             4.5
  Unknown                           302            69.9
  **no of years since diagnosis**                  
  \<1year                           63             12.8
  \> 0r=1 year                      428            87.2
  Total                             491            100.0

###### 

proportion of patients with history of oral lesions suggestive of HIV prior to presentation

                                                      Frequency   Percentage
  --------------------------------------------------- ----------- ------------
  **Oral lesions**                                                
  No lesions ever present                             419         85.3
  Patients with previous lesion                       72          14.7
  **Features of oral lesions**                                    
  Wound /Sores /Ulcers                                22          4.3
  White patch/Thrush                                  16          3.1
  Growth/Swelling                                     10          2.0
  Bleeding                                            6           1.2
  Rashes                                              6           1.2
  Hyperpigmented/black patches                        3           0.6
  Others                                              9           1.8
  Total                                               72          14.7
  **Did lesions clear with ARV**                                  
  Yes                                                 28          40.0
  No                                                  25          35.7
  I don't know                                        19          24.3
  Total                                               72          100
  **Did you have to treat with other medications?**               
  Yes                                                 21          30.0
  No                                                  34          48.6
  I don't know                                        17          21.4
  Total                                               72          100
  **Did the medication/s clear the lesion/s?**                    
  Yes                                                 16          22.9
  No                                                  10          14.3
  I don't know                                        46          62.8
  Total                                               72          100
  **Did lesions ever reoccur?**                                   
  Yes                                                 18          25.7
  No                                                  23          32.9
  I don't know                                        31          41.4
  Total                                               72          100

###### 

clinical presentation of oral lesions of HIV observed during oral examination and medications used

  Clinical presentation and medications used   Frequency   Percentage(%)
  -------------------------------------------- ----------- ---------------
  **Presence of oral lesion**                              
  Yes                                          12          2.4
  No                                           479         97.6
  Total                                        491         100
  **Types of lesions**                                     
  Hyperpigmentation                            10          2.0
  Ulcers                                       2           0.4
  Total lesions seen                           12          2.4
  **Medications used**                                     
  Regimen containing zidovudine                3           37.5
  Regimen containing Tenofovir                 5           62.5
  Regimen containing Efaverenz                 3           37.5
  Regimen containing Lamivudine                6           75
  Regimen containing Emtritabine               2           25
  Regimen containing Nevirapine                5           62.5

Initial CD4+ cell count results were obtained for all patients enrolled into the study to access their level of immunosuppression at diagnosis prior to cART initiation. The initial CD4+ cell count results were available for 459 of the enrolled patients; 199(43.4%) had a CD4+ cell count less than 200/mm^3^ and 194(42.3%) had a CD4+ cell count between 200-500/mm^3^. Frequencies of oral lesions in these patients are shown in [Table 4](#t0004){ref-type="table"}. In this study, only 2 out of the 12 patients with oral lesions suggestive of HIV reported previous episodes of such lesions prior to commencing cART, one was a case of oral ulcer and the other a case of oral hyperpigmentation. Five of the patients with oral lesions had a CD4+ cell count less than 200cell/mm^3^ (group 1), while the other 7 were in group 2 (CD4+ cell count between 200-500 cell/mm3) prior to cART initiation. With the definition of significant immunological response in HIV as a rise in CD+ cell count by100 cells/mm3 after more than 6 months of therapy; 11 of the 12 patients with oral lesions had significant increases in the cell count after 6 months of cART therapy ([Table 5](#t0005){ref-type="table"}). Of the 12 patients who presented with oral lesions of HIV at examination, only 1 had a previous history of oral lesion prior to initiation of cART. Other patients did not have any lesion suggestive of HIV prior to cART initiation. Mean CD4 count in cells/mm3 of these patients was 204.5 (+ 107.7) at initiation of cART and 468.7 (+ 18.5) at presentation, with a median duration of 38.5 (22.5-93.8) months. This showed an improvement in their immune status, yet there was an increase in incidence of oral lesions (p=0.002). There was no statistically significant association between the presence of oral lesions and history of cigarette smoking.

###### 

CD4 Classification of all patients with and without history of oral lesions suggestive of HIV

  CD4        No oral lesions   Sores/ ulcers/ wounds   White patch / candidiasis   Growth    Bleeding   Rashes    Hyperpigmentation   Others     Total
  ---------- ----------------- ----------------------- --------------------------- --------- ---------- --------- ------------------- ---------- ------------
  \>500      56(85%)           3(4.5%)                 1(1.5%)                     0 (0%)    1(1.5%)    2(3.0%)   1(1.5%)             2 (3%)     66(14.3%)
  200-500    169 (87.1%)       8(4.1%)                 3(1.5%)                     7(3.6%)   3(1.5%)    0(0%)     0(0%)               4 (2.2%)   194(42.3%)
  \<199.99   170 (85.5%)       8(4 %)                  10(5%)                      2(1%)     0(0%)      4(2%)     2(1%)               3(1.5%)    199(43.4%)
  Total                                                                                                                                          459(100%)

###### 

oral lesions in relation to the CD4 count of patients before and after cART initiation

  Oral lesions        Duration of cART in months   Previous history of oral lesions prior to cART   CD4 count @ diagnosis   CD4 count @ cART initiation   CD4 count @ examination
  ------------------- ---------------------------- ------------------------------------------------ ----------------------- ----------------------------- -------------------------
  Hyperpigmentation   108                          nill                                             178                     178                           695
  Oral ulcer          120                          nill                                             213                     191                           516
  Hyperpigmentation   12                           Oral ulcers                                      295                     295                           408
  Hyperpigmentation   22                           nill                                             455                     286                           455
  Hyperpigmentation   51                           nill                                             270                     156                           502
  Hyperpigmentation   36                           nill                                             239                     239                           516
  Hyperpigmentation   \-                           Hyperpigmentation                                54                      54                            502
  Hyperpigmentation   41                           nill                                             386                     386                           222
  Oral ulcer          \-                           nill                                             \-                      \-                            \-
  Hyperpigmentation                                                                                 34                      34                            464
  Hyperpigmentation   \-                           nill                                             \-                      \-                            \-
  Hyperpigmentation   36                           nill                                             226                     226                           407

Discussion {#sec4}
==========

Various studies have shown prevalence of HIV-related oral lesions reduced significantly with the use of cART. The reported percentage decrease varied from 10% in a USA study \[[@cit0011]\], 50% in a Mexican study \[[@cit0016]\] and 84% in a previous study in Lagos, Nigeria \[[@cit0007]\]. Studies examining the effect of cART on the prevalence of individual oral manifestations such as oral candidiasis, oral hairy leukoplakia, HIV-related periodontal diseases, Kaposi\'s sarcoma (KS), oral papilloma, and HIV-related salivary gland disease showed reduction in the prevalence of these lesions \[[@cit0004], [@cit0009], [@cit0010], [@cit0016]\]. The current study also agrees with these findings, as 40% of study participants with history of oral lesions prior to commencement of cART reported that the lesion resolved with the use of cART. Though seventy-two (14.7%) of respondents had a history of oral lesions suggestive of HIV prior to administration of cART, only 12 (2.4%) of the patients had lesions at recruitment by which time mean duration on cART was 36 months. This may support the previously mentioned studies of the positive effects of cART administration on oral lesions of HIV \[[@cit0007], [@cit0010], [@cit0019]\]. Eweka *et al.* (2012) in their study showed a high prevalence of oral lesions among cART naive HIV patients (38.4%) but after 3 months of cART administration 84% of the lesions cleared \[[@cit0007]\]. This further showed that with improvement of the immune status there will be a resultant improvement in the oral lesions with cART. The predominant oral manifestation was hyperpigmentation, occuring in 10 out of the 12 participants. The process of hyperpigmentation is complex and the specific mechanisms that causes it in the context of HIV infection are unknown. It may be associated with HIV-induced cytokine dysregulation with the medications commonly prescribed to HIV-seropositive persons, and with adrenocortical dysfunction, which is not uncommon in HIV-seropositive subjects with AIDS \[[@cit0020]\]. Reported prevalence of hyperpigmentation varies from as low as 5.2% in children in Tanzania to as high as 38% in Venezuela \[[@cit0021], [@cit0022]\].

Although it could not be fully ascertained when the oral pigmentation occurred during the course of cART administration, majority of the patients were certain the pigmentation was not present before cART therapy except in one patient who had oral hyperpigmentation prior to cART administration. It was also observed that majority of participants with hyperpigmentation were either on Lamivudine, Tenofovir or nevirapine containing regimen, none of which is known to be associated with hyperpigmentation. The major ARV which has been associated with oral hyperpigmentation is regimen containing zidovudine. \[[@cit0023]\] Zidovudine has an established adverse drug reaction of hyperpigmentation of the skin and nails \[[@cit0024]\]. Though antiretroviral drugs could be responsible for some of the oral hyperpigmentation seen in some studies \[[@cit0025], [@cit0026]\], other research findings suggest some other drugs used in treating concomitant associated diseases such as clofazimine and ketoconazole could increase the α-melanocyte stimulating hormone. On the other hand, some researchers could not find any systemic or local cause for the oral hyperpigmentation and have suggested it may be idiopathic \[[@cit0027], [@cit0028]\]. There was no association between the patients who smoked and those with oral lesions particularly oral hyperpigmentation. Aphthous-like ulcers were seen in 2 of our patients; this condition is seen in HIV patients and categorized by the EEC Clearinghouse as group 2 lesions, (lesions seen in HIV). Aphthous-like ulcer may not necessarily be a direct lesion of HIV as it appeared minimal and could occur in many HIV seronegative patients who are prone to ulcerations. The current study also reported 5 of the patients with oral lesions to have a CD4+ cell count less than 200cell/mm^3^, while the other 7 patients had CD4+ cell count between 200-500 cell/mm^3^) prior to cART initiation. There was significant improvement in the CD4+ cell count after cART administration in 11 of the respondents with post cART oral lesions. These patients gave no prior history of oral lesions related to HIV before initiation of HAART. This further supports our suspicion that the hyperpigmentation may not be a direct manifestation of the disease, but perhaps is a side effect of medications used.

Conclusion {#sec5}
==========

The prevalence of oral lesions in people living with HIV on cART therapy in Lagos is low. Oral hyperpigmentation and oral ulcers are the most frequently observed lesions. As the presence of oral lesions in PLWHIV in this study had no association with their CD4+ cell count; this study therefore infers that oral lesions seen in HIV patients on cART may not be a direct manifestation of the disease.

What is known about this topic {#sec5.1}
------------------------------

-   It has been known that prevalence of oral lesions in HIV seropositive patients reduce considerably after administration of cART due to improvement of their immunity;

-   It is also known that side effects of the antiretroviral medications may manifest as oral lesions within the oral cavity affecting the aesthetics and quality of life of the patients.

What this study adds {#sec5.2}
--------------------

-   With the large population of Nigerians living with HIV/AIDS and on cART, little information has been documented on either the positive or negative effects of these medications on the oral lesions. This paper has therefore added to knowledge by confirming that the prevalence of HIV related oral lesions in patients on cART is low. In addition, presence of oral lesions in People living with HIV in Nigeria does not appear to have any connection with cART therapy.
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